Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Organon ( (OGN) ).
Organon reported robust financial results for Q3 2024, with a revenue increase to $1.582 billion, driven by strong performances in Women’s Health and Biosimilars. Nexplanon and Hadlima fueled growth, despite challenges from generic competition and pricing pressures. The company also narrowed its full-year revenue guidance, reflecting confidence in its strategic execution. Earnings per share rose significantly, benefiting from a tax asset valuation adjustment, highlighting Organon’s disciplined cost management and growth strategy.
Learn more about OGN stock on TipRanks’ Stock Analysis page.
